Red Sox Base Hit: MSKCC Challenges DFCI Key Data Points

摘要

HULTCRANTZ: How would you best use isatuximab/lenalidomide or ixaz-omib/lenalidomide for patients with multiple myeloma? MO: The combination of ixazomib/ lenalidomide won't be ideal for most patients because most will be lenalidomide refractory by the time they reach the second line of therapy. The more interesting question is about the role of ixazomib in combination with other drugs, specifically poma-lidomide. We have some data on that now. The initial results of a phase 1/2 study of twice-weekly ixazomib with pomalidomide and dexamethasone were reported at the 2021 American Society of Hematology Annual Meeting.